CD39 and CD73 in immunity and inflammation

Luca Antonioli, Pál Pacher, E. Vízi, G. Haskó

Research output: Contribution to journalArticle

387 Citations (Scopus)

Abstract

The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively. This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced by adenosine. The CD39/CD73 pathway changes dynamically with the pathophysiological context in which it is embedded. It is becoming increasingly appreciated that altering this catabolic machinery can change the course or dictate the outcome of several pathophysiological events, such as AIDS, autoimmune diseases, infections, atherosclerosis, ischemia-reperfusion injury, and cancer, suggesting these ectoenzymes are novel therapeutic targets for managing a variety of disorders.

Original languageEnglish
Pages (from-to)355-367
Number of pages13
JournalTrends in Molecular Medicine
Volume19
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Adenosine Monophosphate
Adenosine
Immunity
Adenosine Triphosphate
Inflammation
Reperfusion Injury
Adenosine Diphosphate
Autoimmune Diseases
Atherosclerosis
Acquired Immunodeficiency Syndrome
Anti-Inflammatory Agents
Infection
Neoplasms
Therapeutics

Keywords

  • CD39
  • CD73
  • Cytokine
  • Ectonucleotidase
  • Macrophage
  • Neutrophil
  • Sepsis
  • Treg

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Medicine(all)

Cite this

CD39 and CD73 in immunity and inflammation. / Antonioli, Luca; Pacher, Pál; Vízi, E.; Haskó, G.

In: Trends in Molecular Medicine, Vol. 19, No. 6, 06.2013, p. 355-367.

Research output: Contribution to journalArticle

Antonioli, Luca ; Pacher, Pál ; Vízi, E. ; Haskó, G. / CD39 and CD73 in immunity and inflammation. In: Trends in Molecular Medicine. 2013 ; Vol. 19, No. 6. pp. 355-367.
@article{ab4b0ecf4e92436f937a9ef73718b83d,
title = "CD39 and CD73 in immunity and inflammation",
abstract = "The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively. This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced by adenosine. The CD39/CD73 pathway changes dynamically with the pathophysiological context in which it is embedded. It is becoming increasingly appreciated that altering this catabolic machinery can change the course or dictate the outcome of several pathophysiological events, such as AIDS, autoimmune diseases, infections, atherosclerosis, ischemia-reperfusion injury, and cancer, suggesting these ectoenzymes are novel therapeutic targets for managing a variety of disorders.",
keywords = "CD39, CD73, Cytokine, Ectonucleotidase, Macrophage, Neutrophil, Sepsis, Treg",
author = "Luca Antonioli and P{\'a}l Pacher and E. V{\'i}zi and G. Hask{\'o}",
year = "2013",
month = "6",
doi = "10.1016/j.molmed.2013.03.005",
language = "English",
volume = "19",
pages = "355--367",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - CD39 and CD73 in immunity and inflammation

AU - Antonioli, Luca

AU - Pacher, Pál

AU - Vízi, E.

AU - Haskó, G.

PY - 2013/6

Y1 - 2013/6

N2 - The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively. This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced by adenosine. The CD39/CD73 pathway changes dynamically with the pathophysiological context in which it is embedded. It is becoming increasingly appreciated that altering this catabolic machinery can change the course or dictate the outcome of several pathophysiological events, such as AIDS, autoimmune diseases, infections, atherosclerosis, ischemia-reperfusion injury, and cancer, suggesting these ectoenzymes are novel therapeutic targets for managing a variety of disorders.

AB - The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively. This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced by adenosine. The CD39/CD73 pathway changes dynamically with the pathophysiological context in which it is embedded. It is becoming increasingly appreciated that altering this catabolic machinery can change the course or dictate the outcome of several pathophysiological events, such as AIDS, autoimmune diseases, infections, atherosclerosis, ischemia-reperfusion injury, and cancer, suggesting these ectoenzymes are novel therapeutic targets for managing a variety of disorders.

KW - CD39

KW - CD73

KW - Cytokine

KW - Ectonucleotidase

KW - Macrophage

KW - Neutrophil

KW - Sepsis

KW - Treg

UR - http://www.scopus.com/inward/record.url?scp=84878614399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878614399&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2013.03.005

DO - 10.1016/j.molmed.2013.03.005

M3 - Article

C2 - 23601906

AN - SCOPUS:84878614399

VL - 19

SP - 355

EP - 367

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 6

ER -